How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


CLCN2 mutation analysis – Molecular diagnostic of familial hyperaldosteronism type II

Organization name

PROvendis GmbH


More than a billion people worldwide suffer from high blood pressure, which is largely caused by lifestyle habits such as lack of physical exercise, obesity, diet, salt intake and alcohol consumption. Besides that genetic factors play an important role in hypertension. Hyperaldosteronism is supposed to be the most common reason for secondary hypertension accounting for 5 to 12 percent of patients with high blood pressure.

Researchers of the Heinrich Heine University of Düsseldorf together with colleagues from the United States and Australia have identified mutations in the chloride channel encoding gene CNCL2 as a new hyper-tension disease gene. Pedigrees of eight kindreds were analyzed by Sanger sequencing, and mutations were identified as indicated in the figure.

The molecular diagnosis of CLCN2 facilitates better timely and adequate treatment of affected persons with hyperaldosteronism, especially of patients suffering from hyperaldosteronism in childhood and adolescence, and furthermore applies to disease risk assessment. In addition, this technology may give rise to novel therapy options for hyperaldosteronism targeting the mutated chloride channel ClC-2.

Commercial Opportunities

The invention is offered for licensing.

Competitive Advantages

  • First diagnostic option for patients with familial hyperaldosteronism type II
  • Timely and adequate treatment possible
  • Provides risk assessment in reproductive medicine

Current Status

In case of interest we are pleased to inform you about the patent Status.

Relevant Publications

Scholl, U. I., et al. (2018) CLCN2 chloride channel mutations in familial hyperaldo-steronism type II. Nature Genetics doi: 10.1038/s41588-018-0048-5.


To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries